Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Broadcom
AVGO
|
+$67.3M |
| 2 |
Veralto
VLTO
|
+$60.2M |
| 3 |
Newmont
NEM
|
+$43.4M |
| 4 |
Vertiv
VRT
|
+$19.4M |
| 5 |
Webster Financial
WBS
|
+$17.3M |
Top Sells
| 1 |
Apple
AAPL
|
+$328M |
| 2 |
Microsoft
MSFT
|
+$244M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$237M |
| 4 |
VMW
VMware, Inc
VMW
|
+$130M |
| 5 |
NVIDIA
NVDA
|
+$109M |
Sector Composition
| 1 | Technology | 30.91% |
| 2 | Healthcare | 12.91% |
| 3 | Consumer Discretionary | 12.16% |
| 4 | Industrials | 9.36% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Healthcare Services Group
HCSG
$1.2B
| $1.52M | ﹤0.01% |
146,163
-15,800
| -10% | -$164K |
|
2002
MarineMax
HZO
$573M
| $1.51M | ﹤0.01% |
38,900
-6,800
| -15% | -$265K |
|
|
VERV
2003
DELISTED
Verve Therapeutics
VERV
| $1.51M | ﹤0.01% |
108,500
+13,200
| +14% | +$184K |
|
2004
Bank First Corp
BFC
$1.26B
| $1.51M | ﹤0.01% |
17,417
-2,000
| -10% | -$173K |
|
2005
Anavex Life Sciences
AVXL
$823M
| $1.5M | ﹤0.01% |
161,500
-16,200
| -9% | -$151K |
|
2006
B&G Foods
BGS
$369M
| $1.5M | ﹤0.01% |
142,500
-16,200
| -10% | -$170K |
|
2007
CryoPort
CYRX
$474M
| $1.49M | ﹤0.01% |
96,300
-3,800
| -4% | -$58.9K |
|
|
PRSU
2008
Pursuit Attractions and Hospitality, Inc.
PRSU
$1.06B
| $1.49M | ﹤0.01% |
41,200
-4,100
| -9% | -$148K |
|
|
INVX
2009
Innovex International, Inc.
INVX
$1.16B
| $1.49M | ﹤0.01% |
64,000
-7,400
| -10% | -$172K |
|
2010
Arcturus Therapeutics
ARCT
$490M
| $1.49M | ﹤0.01% |
47,200
-5,400
| -10% | -$170K |
|
|
SII
2011
Sprott
SII
$1.78B
| $1.48M | ﹤0.01% |
43,575
-5,400
| -11% | -$183K |
|
2012
Hovnanian Enterprises
HOV
$917M
| $1.48M | ﹤0.01% |
9,500
-900
| -9% | -$140K |
|
2013
Heritage Financial
HFWA
$845M
| $1.48M | ﹤0.01% |
69,068
-8,100
| -10% | -$173K |
|
2014
Zentalis Pharmaceuticals
ZNTL
$113M
| $1.48M | ﹤0.01% |
97,400
-11,000
| -10% | -$167K |
|
2015
Kura Oncology
KURA
$766M
| $1.47M | ﹤0.01% |
102,400
-19,700
| -16% | -$283K |
|
2016
Liberty Live Group Series A
LLYVA
$9.09B
| $1.47M | ﹤0.01% |
+40,276
| New | +$1.47M |
|
2017
REX American Resources
REX
$1.02B
| $1.47M | ﹤0.01% |
31,100
-3,200
| -9% | -$151K |
|
|
INBX
2018
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.47M | ﹤0.01% |
38,700
-18,900
| -33% | -$718K |
|
2019
Portillo's
PTLO
$442M
| $1.47M | ﹤0.01% |
92,300
-10,400
| -10% | -$166K |
|
2020
Ambac
AMBC
$414M
| $1.47M | ﹤0.01% |
89,200
-9,400
| -10% | -$155K |
|
2021
First Mid Bancshares
FMBH
$963M
| $1.47M | ﹤0.01% |
42,400
+1,800
| +4% | +$62.4K |
|
2022
Editas Medicine
EDIT
$244M
| $1.47M | ﹤0.01% |
144,800
-34,400
| -19% | -$348K |
|
2023
Insteel Industries
IIIN
$767M
| $1.47M | ﹤0.01% |
38,300
-4,500
| -11% | -$172K |
|
2024
International Money Express
IMXI
$431M
| $1.46M | ﹤0.01% |
66,300
-9,800
| -13% | -$216K |
|
2025
Gray Television
GTN
$599M
| $1.46M | ﹤0.01% |
163,400
-18,400
| -10% | -$165K |
|